Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
54 participants
INTERVENTIONAL
2023-09-01
2026-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
sham group
receive sham itbs
rTMS
intermittent theta-burst stimulation (iTBS)
low-dose group
receive low dose of itbs
rTMS
intermittent theta-burst stimulation (iTBS)
high-dose group
receive high dose of itbs
rTMS
intermittent theta-burst stimulation (iTBS)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
rTMS
intermittent theta-burst stimulation (iTBS)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 6-12 years old, regardless of gender
* Right-handed
* Han nationality or born in the Han nationality Ghetto
* The course of the disease is greater than 6 months
* Webster children's intelligence ≥ 70
* The patient's guardian agrees and signs an informed consent form.
Exclusion Criteria
* Widespread developmental disorders and other neurological developmental related disorders;
* Complication with other important organ diseases such as heart and lungs;
* Suffering from diseases such as epilepsy and tic disorder;
* Individuals who cannot tolerate rTMS treatment or cannot cooperate with treatment.
* Patients taking psychoactive drugs, antipsychotics, antidepressants, or mood stabilizers 3 months prior to enrollment or during rTMS treatment; In addition to the minimum effective therapeutic dose of Tomoxetine (1.2-1.4 mg • kg/day), there has been systematic use of first-line ADHD drugs in clinical practice Webster's intelligence\<70
* Implantation of metal and electronic components in the body (excluding the oral cavity), such as pacemakers;
6 Years
12 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
First Affiliated Hospital of Zhejiang University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hu ShaoHua
professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Shaohua Hu, Dr
Role: STUDY_CHAIR
Zhejiang University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Psychiatry, First Affiliated Hospital of Zhejiang University
Hangzhou, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Hu ShaoHua
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IIT20220110C-R2
Identifier Type: -
Identifier Source: org_study_id